The Latest Analyst Ratings for Protagonist Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish and somewhat bullish ratings for Protagonist Therapeutics (NASDAQ:PTGX) in the last quarter. The average 12-month price target for the company is $36.33, which has increased by 2.34% over the past month.
November 03, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protagonist Therapeutics has received positive ratings from analysts, with an increasing 12-month price target.
The bullish and somewhat bullish ratings from analysts indicate a positive outlook for Protagonist Therapeutics. The increasing 12-month price target also suggests that analysts expect the company's stock price to rise in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100